MFT
FOLD

Moisand Fitzgerald Tamayo’s Amicus Therapeutics FOLD Stock Holding History

Moisand Fitzgerald Tamayo’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-100
Closed -$1K – 755
2022
Q2 		$1K Sell
100
-98
-49% -$807 ﹤0.01% 504
2022
Q1 		$2K Buy
+198
New +$1.86K ﹤0.01% 375

Other funds holding FOLD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Moisand Fitzgerald Tamayo's FOLD Position: Q3 2022 in Review

Moisand Fitzgerald Tamayo sold out of Amicus Therapeutics (FOLD) in Q3 2022, closing a stake of 100 shares — an estimated $1K sold.

Moisand Fitzgerald Tamayo first reported a position in FOLD in Q1 2022 and held it in 2 quarters. The position peaked at $2K in Q1 2022. 222 funds tracked by Wall St. Rank hold FOLD as of Q3 2022.

  • Moisand Fitzgerald Tamayo reported no remaining Amicus Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Moisand Fitzgerald Tamayo sold 100 Amicus Therapeutics shares in Q3 2022, an estimated $1K.
  • Moisand Fitzgerald Tamayo first reported a position in Amicus Therapeutics in Q1 2022 and held it in 2 quarters.
  • Moisand Fitzgerald Tamayo's Amicus Therapeutics position peaked at $2K in Q1 2022.
  • 222 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2022.

Based on Moisand Fitzgerald Tamayo's 13F filing for Q3 2022, filed 26 Oct 2022.